Bedrijfsoverzicht
Novavax, Inc. is a biotechnology enterprise focused on the discovery, development, and commercialization of vaccines designed to prevent serious infectious diseases across the United States, Europe, and international markets. The company operates within the healthcare sector, specifically inside the biotechnology industry, where it specializes in creating immunological products such as the COVID-19 vaccine Nuvaxovid and the R21 Matrix-M adjuvant malaria vaccine. This specialized operational scope places the firm in a high-risk, high-reward environment dependent on regulatory approvals and global health crises. In terms of scale, the entity manages a market capitalization of $1.32B and generated annual revenue of $1.12B while employing 749 individuals. These financial figures indicate that Novavax holds a mid-to-large cap status within the biotechnology landscape, possessing sufficient liquidity to fund research and development while maintaining a significant operational footprint.
Financiële gezondheid
The company reported a total revenue of $1.12B and a net income of $440.30M for the trailing twelve months, with an EBITDA of $590.85M. The substantial gap between the $1.12B revenue and the $440.30M net income reveals a robust cost structure where operating expenses and taxes consume approximately 60.8% of total sales, yet the company remains highly profitable. However, the free cash flow stands at $-331,942,880, indicating that despite accounting profitability, the company is currently burning cash, which limits its immediate financial flexibility for capital expenditures or acquisitions without external funding. The gross margin is 63.5%, suggesting that the company retains a high portion of revenue after direct production costs, which is typical for vaccine manufacturing. The operating margin of 14.2% and profit margin of 39.2% further demonstrate efficient management of overhead and the ability to convert revenue into bottom-line profit. On the balance sheet, the company holds $735.08M in cash against $278.05M in debt, while the debt-to-equity ratio is listed as N/A. This liquidity position suggests a conservative approach to leverage, as the cash reserves significantly exceed total debt obligations. The current ratio is 2.13, which indicates a strong short-term liquidity position where current assets are more than twice the value of current liabilities. Finally, the return on equity is N/A and the return on assets is 25.7%, with the latter highlighting an exceptionally efficient use of total assets to generate income relative to the company's asset base.
Waarderingsbeoordeling
The trailing P/E ratio is 3.15, while the forward P/E is -8.01, implying that the market expects earnings to be negative in the near future or that the current earnings do not yet reflect future projected profitability. The price-to-book ratio is -10.33, a negative figure that typically indicates the market is pricing the stock below its book value, potentially reflecting concerns about future earnings or specific asset impairments rather than a standard premium. The price-to-sales ratio is 1.18, and the EV/EBITDA is 1.47; these alternative metrics suggest the company is valued at a premium relative to its sales but at a very low multiple relative to its earnings before interest, taxes, depreciation, and amortization. The stock has traded between a 52-week high of $11.97 and a 52-week low of $5.80. Without the specific current share price to calculate the exact percentage difference, the valuation range remains bounded by these extremes, showing significant volatility over the past year. The beta value is 2.65, which means the stock is expected to be 165% more volatile than the broader market, exposing investors to higher fluctuations in price relative to general market movements.
Growth & Income
The revenue growth year-over-year is 66.6%, whereas the earnings growth year-over-year is N/A, indicating that while top-line sales are expanding rapidly, the company's historical earnings data does not currently support a calculated growth rate comparison. Since the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it reinvests its substantial earnings and cash reserves directly into research, development, and commercialization efforts to fuel future expansion. The absence of a dividend payout ratio means there is no historical distribution of cash to shareholders, aligning the company's strategy with capital appreciation and operational scaling rather than income generation. Overall, Novavax presents a high-growth profile characterized by significant revenue expansion and a focus on reinvestment, coupled with a volatile market valuation driven by its beta and negative forward earnings multiples.